Granted Patent
B1
US 12,286,433 · App. 18/915,221 · Granted Apr 29, 2025
Azaindole rock inhibitors
Assignee:
Avicenna Biosciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention provides rho-associated protein kinase (ROCK) inhibiting compounds for therapeutic applications as described further herein.
Claims (1)
1. A compound of structure:
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 3, 2025
From: KAISER, THOMAS MAXWELL
To: AVICENNA BIOSCIENCES, INC.
Reel/Frame 070091/0908 →
Continuity (3)
Continuation
PCTUS2023086402
· Dec 29, 2023
Provisional Application
63436408
· Dec 30, 2022
References Cited (43)
US 6858638B2
· Damour et al.
· 2005
[cited by applicant]
US 20090029970A1
· Takeshita
· 2009
[cited by applicant]
US 20220273662A1
· Oh et al.
· 2022
[cited by applicant]
US 20230257376A1
· Li et al.
· 2023
[cited by applicant]
US 20230312530A1
· Zhao et al.
· 2023
[cited by applicant]
WO WO2009023179A2
· 2009
[cited by applicant]
WO WO2009155209A1
· 2009
[cited by applicant]
WO WO2011050245A1
· 2011
[cited by applicant]
WO WO2021214200A1
· 2021
[cited by applicant]
WO WO2023139379A1
· 2023
[cited by applicant]
WO WO2023209692A1
· 2023
[cited by applicant]
Bye, Nicole et al. “Rho kinase inhibition following traumatic brain injury in mice promotes functional improvement and acute neuron survival but has little effect on neurogenesis, glial responses or neuroinflammation”, …
[cited by applicant]
Chowdhury, Sarwat et al. “Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).”
[cited by applicant]
Defert, Olivier and Sandro Boland “Rho kinase inhibitors: a patent review (2014-2016).”
[cited by applicant]
Duffy, Philip et al. “Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord.”
[cited by applicant]
Feng, Yangbo et al. “Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.”
[cited by applicant]
Feng, Yangbo and Philip V. LoGrasso “Rho kinase inhibitors: a patent review (2012-2013).”
[cited by applicant]
Feng, Yangbo et al. “Rho kinase (ROCK) inhibitors and their therapeutic potential.”
[cited by applicant]
Glyn, Richard J. and Graham Pattison. “The effects on lipophilicity of replacing oxygenated functionality with their fluorinated bioisosteres”, 2021.
[cited by applicant]
International search report and written opinion for PCT/US23/86402, 10 pages, mailed on May 23, 2024.
[cited by applicant]
Koch, Jan Christoph et al. “ROCK inhibition in models of neurodegeneration and its potential for clinical translation.”
[cited by applicant]
Koch, Jan C. et al. “Compassionate use of the ROCK inhibitor fasudil in three patients with amyotrophic lateral sclerosis.”
[cited by applicant]
Li, Xiaohong et al. “PRKX critically regulates endothelial cell proliferation, migration, and vascular-like structure formation.”
[cited by applicant]
Lingor, Paul et al. “ROCK-ALS: protocol for a randomized, placebo-controlled, double-blind phase IIa trial of safety, tolerability and efficacy of the rho kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosis…
[cited by applicant]
Lograsso, Philip V. and Yangbo Feng “Rho kinase (ROCK) inhibitors and their application to inflammatory disorders.”
[cited by applicant]
Moskal, Natalia et al. “ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway.”
[cited by applicant]
Naseer, Shahmir et al. “Traumatic brain injury leads to alterations in contusional cortical miRNAs involved in dementia”, Biomolecules 12.10, 1457, 2022.
[cited by applicant]
Rikitake, Yoshiyuki and James K. Liao “ROCKs as therapeutic targets in cardiovascular diseases.”
[cited by applicant]
Roser, Anna-Elisa, Lars Tönges and Paul Lingor “Modulation of microglial activity by Rho-kinase (ROCK) inhibition as therapeutic strategy in Parkinson's disease and amyotrophic lateral sclerosis.”
[cited by applicant]
Sessions, E. Hampton et al. “Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).”
[cited by applicant]
Staiger, B. “Pharmaceutical Dosage Forms: A Review”, 2017 first published; 2018 last updated, https://walrus.com/articles/ pharmaceutical-dosage-forms-a-review, 2017.
[cited by applicant]
Sun, Shaoyi, and Jianmin Fu “Methyl-containing pharmaceuticals: Methylation in drug design”, Bioorganic & medicinal chemistry letters 28.20, 3283-3289, 2018.
[cited by applicant]
Tatenhorst, Lars et al. “Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.”
[cited by applicant]
Wang, Qing et al. “Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases.”
[cited by applicant]
Weber, Audrey J. and Jeremy H. Herskowitz “Perspectives on ROCK2 as a Therapeutic Target for Alzheimer's Disease.”
[cited by applicant]
Yin, Yan et al. “Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.”
[cited by applicant]
US, 2024/0246972 A1, U.S. Appl. No. 18/610,041, Thomas Maxwell Kaiser, filed Jul. 25, 2024.
[cited by applicant]
US, 2024/0254124 A1, U.S. Appl. No. 18/610,051, Thomas Maxwell Kaiser, filed Aug. 1, 2024.
[cited by applicant]